The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations
- 23 December 2025
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (3) , 326-332
Abstract
Mutations in the DNMT3A gene are not yet classified as a distinct prognostic group in the latest European Leukemia Net (ELN) 2022 genetic risk classification of AML. We analyzed 1888 adult AML patients with ELN 2022 intermediate- or poor-risk cytogenetics who received their first allo-transplant in first complete remission between 2015 and 2022. Among patients with cytogenetically normal AML, the triple-positive mutation group (DNMT3A, NPM1, and FLT3-ITD) was the most frequent (n = 340, 29%), while DNMT3A co-occurrence with either FLT3 or NPM1 mutations alone was less common (4% and 9%, respectively). Patients with DNMT3A mutations were less likely to have a secondary AML (14% versus 24%, p < 0.001). DNMT3A mutations negatively affected post-transplant leukemia-free survival (LFS) in patients with normal karyotype and NPM1 mutation without FLT3-ITD (2-year LFS: 70% versus 90%, hazard ratio [HR]: 3.3, p = 0.006), and increased relapse incidence (RI) in FLT3-ITD and wild-type NPM1 subgroup (2-year RI: 30% versus 18%, HR: 2.32, p = 0.03). Notably, patients with normal karyotype and triple-positive mutation exhibited excellent 2-year LFS and OS (61% and 70%), indicating that allo-transplant overcomes the dismal outcome of this group. The impact of DNMT3A mutations on post-transplant outcomes in AML patients in first remission varies based on karyotype and co-mutations.Keywords
This publication has 24 references indexed in Scilit:
- Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 InhibitorsCurrent Treatment Options in Oncology, 2024
- Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remissionLeukemia & Lymphoma, 2023
- Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesBone Marrow Transplantation, 2022
- Dnmt3a-null hematopoietic stem and progenitor cells expand after busulfan treatmentExperimental Hematology, 2020
- DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational patternLeukemia, 2019
- The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLAmerican Journal of Hematology, 2019
- Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2016
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010